Apr 10 |
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
|
Apr 9 |
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
|
Mar 7 |
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
|
Mar 6 |
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
|
Feb 27 |
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
|
Feb 7 |
BriaCell shares rise on strong data from breast cancer treatment study
|
Feb 7 |
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
|
Feb 6 |
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
|
Jan 31 |
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
|
Jan 4 |
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
|